NeoGenomics (NASDAQ: NEO) has announced that it will debut its PanTracer Family genomic profiling tests for advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) in Chicago May 30—June 3, 2025.
The company also intends to unveil its new AI-driven spatial proteomics platform—Paletrra—designed to provide actionable insights from tissue samples, at ASCO.
In a statement, Warren Stone, president and COO of NeoGenomics, said, “The debut of the PanTracer Family and Paletrra represents a significant milestone for NeoGenomics and a step forward in precision oncology. By equipping clinicians and drug developers with the tools to make faster, more informed decisions, we‘re helping transform cancer care and accelerate innovation across the continuum of oncology diagnostics.”
